AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04600908 — intervention group
Intervention type: OTHER
Intervention: Characteristics of accidents
Description: informations about commuting accidents were recorded either during an occupational medicine consultation or by the medical service after reception of the medical certificate and the administrative declaration
Study NCT05644366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Control Balance Assessment
Description: Postural Stability Testing Each subject was instructed to stand in a static bipedal posture on the MatScan® pressure mat and performed 8 balance tasks.
Study NCT01078766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIMT+HABIT
Description: The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
Study NCT02392182 — intervention group
Intervention type: OTHER
Intervention: Fiberoptic bronchoscopy
Description: All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
Study NCT03517631 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: shRNA-modified CD34+ cells
Description: Infusion of CD34+ cells transduced with shRNAs.
Study NCT03517631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose busulfan preconditioning
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.
Study NCT03517631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan preconditioning
Description: A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.
Study NCT03647813 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Patients received three irradiations of laser at ʎ = 808 nm, 100 mW, 142 J/cm2 and 4 J per point.
Study NCT03647813 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The same laser protocol was followed but with the device switched off.
Study NCT02773953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T4PTelemonitoring
Description: addition of a Telemonitoring unit on the CPAP line to standard care.
Study NCT04689776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Training
Description: The programs are based on dual-task trainings which contain cognitive training and exercise simultaneously. For physical exercise, we will design the programs that involve balance or strength training components in the aerobic exercises. In terms of cognitive training, we will design self-made teaching aids and board games to train different domains of cognitive functions. We plan to assess the participants before and after the intervention programs. We expect that elders receiving dual-task training will improve on outcome measures, and the group with more frequency will have better performance. The results of the study will provide evidence of interventions for elderly with cognitive decline, thereby reducing the burden on their caregivers and the cost of medical resource.
Study NCT04228185 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy
Description: Comparison of banded and not-banded sleeve gastrectomy
Study NCT04228185 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sleeve gastrectomy
Description: Comparison of banded and not-banded sleeve gastrectomy
Study NCT01610635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced versus standard intervals between blood donations
Description: Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
Study NCT02773953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: CPAP treatment for treatment of obstructive sleep apnea syndrome
Study NCT02773953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP treatment for treatment of obstructive sleep apnea syndrome
Study NCT01256294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Tacrolimus
Description: Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
Study NCT01256294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic Tacrolimus
Description: Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
Study NCT01256294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branded Tacrolimus
Description: Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
Study NCT01256294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Branded Tacrolimus
Description: Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
Study NCT04681352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octave-Ultherapy treatment
Description: Micro-focused ultrasound delivered below the surface of the skin.
Study NCT03625843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness exercises
Study NCT03220451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive elastic taping
Description: Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
Study NCT01643772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Description: The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
Study NCT00232791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cypher Select
Description: CYPHER SELECT™ Sirolimus-eluting Coronary Stent
Study NCT00232791 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher
Description: CYPHER™ Sirolimus-eluting Coronary Stent
Study NCT01617226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Azacitidine both arms; 75mg/m\^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
Study NCT01305863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ASC coated ePTFE vascular graft
Description: An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
Study NCT01305863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propaten graft
Description: 6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
Study NCT01420484 — intervention group
Intervention type: OTHER
Intervention: different blood pressure intervals
Description: In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
Study NCT02058147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/lixisenatide Fixed Ratio Combination
Description: Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Study NCT02058147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
Study NCT02058147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
Study NCT01617226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorinostat
Description: Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT03179904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denifanstat
Description: Given PO
Study NCT02058147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration.
Study NCT02058147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: Tablet; Route of administration: Oral administration.
Study NCT03840330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: High-intensity interval training group
Description: 16 weeks of High-intensity interval training
Study NCT03840330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Moderate-intensity interval training group
Description: 16 weeks of Moderate-intensity interval training
Study NCT02153567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
Study NCT02153567 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given for the next 10 weeks.
Study NCT03836300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Infant Inter(X)action Intervention (PIXI)
Description: Psychoeducation around the diagnosed disorder, early development, and service navigation along with parent-child interaction activities, parent coaching, and family/parent well-being support.
Study NCT01639872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
Study NCT01639872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
Study NCT01046500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: myo-inositol
Description: 2 grams twice a day
Study NCT01046500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: pill, 250 mg, twice a day
Study NCT03603041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein
Description: Participants in the protein arms will receive whey protein daily for 16 weeks.
Study NCT03603041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Whey protein
Description: Participants in the protein arms will receive whey protein daily for 16 weeks.
Study NCT03603041 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: Participants in the omega-3 fatty acid arms will receive capsules daily for 16 weeks.
Study NCT01405053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rufinamide
Description: Rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
Study NCT01405053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Any other approved Antiepileptic Drug
Description: Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
Study NCT02981069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg
Study NCT02981069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
Study NCT02981069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Dapagliflozin
Study NCT03459573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Track
Description: Participants with T2D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
Study NCT03459573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts On Call
Description: Participants with T1D will use One Drop's digital therapeutics solution (app, meter, and 'On Track' in-app coaching) for 3 months
Study NCT03459573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One Drop | Experts Revive
Description: Participants with pre-diabetes will use One Drop's digital therapeutics solution (app, meter, and 'Revive' in-app coaching) for 3 months
Study NCT00804388 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: 32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
Study NCT03102229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care - Status Checks
Description: Would occur everyday during treatment when a patient is deemed high-risk.
Study NCT03102229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Supportive Care - Referrals
Description: On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
Study NCT04178772 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue Moist Multifocal Contact Lens JJVC Marketed Contact Lens
Description: JJVC Marketed Contact Lens
Study NCT01889849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIP 48
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Study NCT01889849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIP 48
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Study NCT01889849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Study NCT01889849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
Study NCT00887757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: 150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study NCT00887757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
Study NCT02282969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
Study NCT02282969 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
Study NCT01214785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provision of household latrines
Description: WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
Study NCT00067704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma writing
Study NCT00067704 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Writing about daily events
Study NCT03588377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Oximetry
Description: Intervention clusters:~On LHW's regular visits to households of their catchment area, they will daily screen for severe pneumonia and check oxygen level in blood using a pulse oximeter in all under \<5 children with symptoms of cough or difficulty breathing~Case definition:~1. Birth - 6 days: Fast breathing +/- Low oxygen in blood \<92% (Hypoxemia)~2. 7 days - 59 months: Fast breathing and/or Chest In-drawing + Any one danger sign: (Low oxygen in blood \<92% (Hypoxemia), Refusing to eat, Vomiting continuously, Convulsions, Lethargy/ Unconsciousness, Stridor.
Study NCT04289896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Description: The plyometric program to be followed by the subjects assigned to the experimental group during the four weeks includes: Squat jumps, alternate lunge, cyclic horizontal jump, horizontal left leg jump, horizontal right leg jump, vertical left leg jump, right leg vertical jump, squat box jumps, box jumps left leg, box jumps right leg, box to box squat jumps, box to box left leg, box to box right leg.~In all the exercises the subjects will be able to help themselves with the arms and a rest period of 120 seconds will be left between each series.~The intervention will be carried out prior to training, keeping a minimum of 48 hours of rest between sessions.
Study NCT01916629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Photocil for Psoriasis
Description: Photocil for Psoriasis
Study NCT01916629 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sunscreen (SPF 2)
Description: Placebo - Sunscreen (SPF 2)
Study NCT04538391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local ifiltration Bupivacaine, Meloxican and placebo
Description: no other intervention done
Study NCT04591054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extended Vision IOL
Description: Vivity IOL implantation following cataract extraction
Study NCT04591054 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Aspheric Monofocal IOL
Description: enVista IOL implantation following cataract extraction
Study NCT01751971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inspired oxygen (40%)
Description: Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
Study NCT01751971 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Inspired oxygen (40%)
Description: Supplemental oxygen at 40% inspired via venturi mask (15 L/min). Equivalent to 5 L/min via nasal cannula.
Study NCT01751971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: Medical air with 21% oxygen via venturi mask (15 L/min).
Study NCT01751971 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Medical air with 21% oxygen via venturi mask (15 L/min).
Study NCT01265680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
Study NCT03856151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HEALTHY BOX Powered heating pad (electronic moxibustion)
Description: Using heating pad (electronic moxibustion) with insulating materials on low temperatures (56±8℃) in treating patients with intra-dialytic hypotension
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Irreversible proteasome inhibitor
Study NCT03773107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carfilzomib
Description: Irreversible proteasome inhibitor
Study NCT01649947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.~Prior to receiving paclitaxel, all patients will receive the following premedication:~* Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv \< 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)~* Diphenydramine 50 mg iv (or equivalent) \< 1 hour prior to paclitaxel infusion~* Ranitidine 50 mg iv \< 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)
Study NCT01649947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
Study NCT01649947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.